This cohort study assesses the risk of fractures associated with sodium-glucose cotransporter 2 inhibitors vs incretin-based drugs of dipeptidyl-peptidase 4 inhibitors and glucagon-like peptide 1 receptor agonists, separately, in postmenopausal individuals with type 2 diabetes. Here, DPP4 is linked to type 2 diabetes mellitus.